您好!欢迎来到化工e站网 登录 注册
我的EWeb ▼
导航菜单 ▼
中文 ▼
医药中间体
无机化工
有机原料
原料药
染料及颜料
表面活性剂
香精与香料
化学试剂
食品添加剂
催化剂及助剂
分析化学
首页 化工产品目录 医药中间体 原料药中间体 L-甲状腺素钠五水合物(左甲状腺素钠)
6106-07-6
L-甲状腺素钠五水合物(左甲状腺素钠)
产品纠错
CAS号:6106-07-6 | 英文名称:Sodium levothyroxine pentahydrate
分子式 C15H20I4NNaO9
分子量 889
EINECS号 682-494-3
MDL MFCD00149110
Smiles
InChIKey
L-甲状腺素钠五水合物(左甲状腺素钠)化学百科
基本信息
中文名称 左旋甲状腺素钠五水合物
英文名称 Sodium levothyroxine pentahydrate
CAS号 6106-07-6
分子式 C15H20I4NNaO9
分子量 888.93
EINECS号 682-494-3
物化性质
熔点 207-210 (dec.)(lit.)
比旋光度 [α]D20 +15~+19°
密度 2.381
溶解度 在细胞培养基的溶解度为0.1 mg/mL
形态 粉末
颜色 白色到黄色到橙色
BRN 5721845
安全信息
危险品标志 Xn
危险类别码 40
安全说明 22-24/25-36
WGK Germany 3
RTECS号 YP2833760
生产及用途
L-Thyroxine sodium salt pentahydrate (Levothyroxine; T4) 是一种合成的甲状腺激素,用于甲状腺功能减退症的研究。DIO 酶将 L-Thyroxine (T4) 转化成具有生物活性的三碘甲状腺氨酸 (T3)。

Thyroid Hormone Receptor

Deiodinases (DIOs), which catalyse the conversion of thyroxine (pro-hormone) to the active thyroid hormone, are associated with thyroid stimulating hormone (TSH) levels. DIO1 and DIO2 catalyze activation of thyroid hormone secretion in contrast to DIO3 playing role inactivation of the secretion. Activities of DIO1 and DIO2 play pivotal role in the negative feedback regulation of pituitary TSH secretion. L-Thyroxine (T4) and Triiodothyronine (T3) hormones are known to modulate the expression of ionic channels, pumps and regulatory contractile proteins. Moreover, thyroid hormones have been shown to influence calcium homeostasis and flux responsible for excitation and contractility, with L-Thyroxine and Triiodothyronine modulating its pharmacological control and secretion. In rats fed 12 weeks with the iodine-free diet, a significant decrease in the levels of both Triiodothyronine and L-Thyroxine is observed when compared to the control group fed with standard diet (p<0.001). In the group treated with low doses of L-Thyroxine, an increase in L-Thyroxine levels is observed (p=0.02) while Triiodothyronine levels remain virtually similar to the control group (p=0.19). Rats treated with high doses of L-Thyroxine display a significant increase in both Triiodothyronine and L-Thyroxine circulating concentrations compared to the non-treated hypothyroid group (p<0.001 and p=0.004, respectively) and a significant increase in L-Thyroxine levels when compared to the control values (p=0.03).

上下游产品
上游产品共计:0
下游产品共计:0
产品供应商